Cancer is a complex and heterogeneous disease that arises from the disruption of normal cellular functions through genetic or epigenetic changes. To better understand the underlying mechanisms Hanahan and Weinberg created a list of 11 cancer hallmarks and two enabling traits which include: self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, reprogramming energy metabolism and evading immune response, and the two enabling traits: genome instability and mutation, and tumor-promoting inflammation. Cell Signaling Technology (CST) has significant expertise backed by an extensive catalog of exceptionally reliable, sensitive, and validated products in support of diverse and dynamic cancer research needs from development of novel therapeutics to discovering new insights into cancer pathogenesis.
The 11 hallmarks of cancer as described by Hanahan and Weinberg provide an organizational structure for understanding cancer cell genotypes and assisting in development of novel therapeutics. CST offers the tools to interrogate these hallmarks through a comprehensive catalog of reliable and validated antibodies that target the following mechanisms: sustaining proliferative signaling, evading growth suppressors, avoiding immune destruction, enabling replicative immortality, tumor promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and mutation, and resisting cell death.
Cell-based assays in cancer research are important tools for probing signaling pathways involved in tumorigenesis and metastasis. CST offers a variety of assays and kits that aid in the characterization of important cancer mechanisms and cellular pathways including: ALK and ROS1, caspase-3 activity, epigenetic biomarkers, and regulators and histone modifications for across a range of cancer types.